Europe
United Kingdom
Europe
United Kingdom

The 'go to' European specialist pharma company

Key facts

Norgine fact sheet

 

We are a European specialist pharmaceutical company, established in 1906.  We provide expertise and ‘know how’ in Europe to develop, manufacture and market products that offer real value to healthcare professionals, payers and patients.

 

Norgine’s approach and infrastructure is integrated and focused upon ensuring that Norgine wins partnership opportunities for growth.

 

Our locations

 

Norgine is headquartered in the Netherlands and its global operations are based in Amsterdam and in Harefield, UK. Norgine owns an R&D site in Hengoed, Wales and two manufacturing sites, one in Hengoed, Wales and one in Dreux, France.

 

Overall, Norgine has sites and offices in the UK (Harefield and Hengoed), France (Rueil and Dreux), Germany (Marburg), Belgium (Heverlee), The Netherlands (Amsterdam), Nordics (Copenhagen), Switzerland (Muttenz), Austria (Vienna), Italy (Milan), Portugal (Lisbon) and Spain (Madrid). Outside Europe, Norgine has offices  in Australia and New Zealand (Sydney).

 

Our employees

 

Norgine employs over 1,100 employees. We have demonstrated manufacturing, clinical development, medical, pharmacovigilance, regulatory, market access, sales and marketing expertise across Europe.

 

2015 performance

 

Total revenue €317M - Net sales €300M - Other income €17M

Product Sales €M

Product Indication Product sales (€m)
2014 2015 Growth
MOVICOL Constipation 161 158 (2)%
MOVIPREP Bowel preparation 45 50 12%
XIFAXAN Hepatic encephalopathy and travellers diarrhoea 22 33 52%
DANTRIUM Malignant hyperthermia 9 11 22%
NORMACOL Constipation 10 10 -
FIVASA Ulcerative colitis and Crohn's disease  8 8 -
KLEAN PREP Bowel preparation 8 7 (12)%
NORMACOL ENEMA Constipation 7 7 -
Other Poducts    15 16 6%
TOTAL    284 300 6%

 

Key partnering milestones

 

Partnering is core to our business. Our approach to partnering is flexible which helps to meet the challenges faced by the pharmaceutical sector. We find and work with partners with complementary skills and a shared vision for improving healthcare.

 

Partnering activities

 

 
Norgine entered into an agreement with Noventure S.L., under which Norgine will distribute GELSECTAN® in Spain, Portugal and Andorra March 2017  

Norgine enters co-promotion agreement with Pfizer in Germany for INFLECTRA® (infliximab) for the treatment of Crohn’s disease and ulcerative colitis

September 2016  
Norgine licensed out NER1006 (PLENVU) to Valeant Pharmaceuticals for US and Canada August 2016  

Norgine divests its MENA operations and product rights to Acino

June

2016

 

Norgine expands its partnership with A Pharm s.r.l. to distribute ZIVEREL® in Austria, Belgium, Denmark, Finland, Germany, Ireland, Luxembourg, the Netherlands, Norway, Sweden, Switzerland and the UK

April

2016

 
Norgine completes agreement with Aspen for the divestment of its South African operations and product rights to Aspen Sept. 2015  
Norgine sell all rights in the UK for NORGALAX® (Docusate Sodium)  July 2015

Norgine entered an agreement with Apharm s.r.l. to distribute ZIVEREL® in Spain, Australia and New Zealand.

June 2015
Norgine acquires a 70% stake in Arc Medical Design Ltd. while retaining Arc Medical Design existing management, who will retain a 30% ownership stake. April 2015
Norgine partners with Arc Medical Design Ltd. for endoscopic device, ENDOCUFF VISION™ March 2015
Norgine and Navidea enter European partnership for LYMPHOSEEK® March 2015

 

Our pipeline

 

We operate in three core therapy areas – gastroenterology, hepatology, critical and supportive care.

 

Please see our latest pipeline on our development pipeline page